Market news

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist at the 13th Aging Research and Drug Discovery Meeting (ARDD 2026), being held October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University in Boston, MA.

Tipranks Press Release.

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026.

Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer,